RedHill Biopharma (RDHL) EBT: 2009-2024
Historic EBT for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$8.3 million.
- RedHill Biopharma's EBT rose 231.03% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 75.62%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
- Latest data reveals that RedHill Biopharma reported EBT of -$8.3 million as of FY2024, which was down 134.57% from $23.9 million recorded in FY2023.
- In the past 5 years, RedHill Biopharma's EBT registered a high of $51.2 million during FY2020, and its lowest value of -$97.7 million during FY2021.
- In the last 3 years, RedHill Biopharma's EBT had a median value of -$8.3 million in 2024 and averaged -$18.7 million.
- Per our database at Business Quant, RedHill Biopharma's EBT tumbled by 290.92% in 2021 and then surged by 133.37% in 2023.
- Yearly analysis of 5 years shows RedHill Biopharma's EBT stood at $51.2 million in 2020, then slumped by 290.92% to -$97.7 million in 2021, then climbed by 26.68% to -$71.7 million in 2022, then spiked by 133.37% to $23.9 million in 2023, then crashed by 134.57% to -$8.3 million in 2024.